Corbus Pharmaceuticals Holdings ((CRBP)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corbus Pharmaceuticals Holdings is conducting a Phase 1/2 clinical study titled A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors. The study aims to determine a safe and effective dose of CRB-701 for treating solid tumors expressing the nectin-4 protein, with the ultimate goal of identifying which cancers can be effectively treated with this drug.
The intervention being tested is CRB-701, a nectin-4 targeted antibody-drug conjugate, administered via intravenous infusion. In some cohorts, it is combined with an anti-PD-1 checkpoint inhibitor to potentially enhance efficacy.
The study follows an interventional design with randomized allocation and a sequential intervention model. There is no masking involved, and the primary purpose is treatment. The study is structured in three parts: dose escalation, dose optimization, and dose expansion.
Key dates for the study include a start date of February 8, 2024, with the latest update submitted on May 29, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
This clinical update may influence Corbus Pharmaceuticals’ stock performance positively if the results show promise, as it could lead to a competitive edge in the oncology market. Investors should watch for further developments, especially in comparison to other companies targeting similar cancer treatments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.